PMVK

Across TCGA pan-cancer cohorts, PMVK mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PMVK data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PMVK mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PMVK expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PMVK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.884	0.656	.011	25	view →
LUAD	OS	Median	All	1.000	0.747	.002	19	view →
CCRCC	OS	Quartile	All	1.000	0.540	.022	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	OS	Median	All	1.000	0.936	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PMVK–HNSC (DFS)

Open the HNSC breakdown →